Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27752296 | 0.98 | LMNA (0.48) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL5242838 | 0.86 | NOTUM (0.43) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL7358278 | 0.83 | GAA (0.57) | POLBGAASMN1; SMN2TSHRKDM4E | |
| SCHEMBL6220609 | 0.82 | CPN1 (0.51) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL3436040 | 0.82 | LMNA (0.47) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL28435105 | 0.82 | CA12 (0.41) | LMNAGAASMN1; SMN2KDM4EALDH1A1 | |
| Cyclopropane Carboxylic Acid SCHEMBL2953576 | 0.81 | TSHR (0.51) | LMNAL3MBTL1POLBSMN1; SMN2PLG | |
| Cyclopropane Carboxylic Acid SCHEMBL2952690 | 0.81 | CHRNB2 (0.57) | LMNAL3MBTL1SMN1; SMN2PLGPLAT | |
| Hydrochloric Acid SCHEMBL7278304 | 0.80 | CPN1 (0.50) | LMNAL3MBTL1MAPTRAB9APOLB | |
| SCHEMBL587681 | 0.80 | LMNA (0.53) | LMNAL3MBTL1MAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081507-B1 | CHEMICAL COMPOUNDS TARGETING THE EYE AND USE THEREOF IN THE TREATMENT OF EYE DISEASES | BIOPHYTIS (FR) | 2023-11-22 | — | — | EP | claimed |
| CN-115335359-A | Ocular targeting compounds and their use in treating ocular diseases | 比奥菲蒂斯公司 | 2022-11-11 | — | — | CN | claimed |
| WO-2021130451-A1 | CHEMICAL COMPOUNDS TARGETING THE EYE AND USE THEREOF IN THE TREATMENT OF EYE DISEASES | BIOPHYTIS (FR) | 2021-07-01 | — | — | WO | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| CN-119930589-A | Tricyclic compound, pharmaceutical composition and application | 广州国家实验室 | 2025-05-06 | — | — | CN | disclosed |
| CN-115335359-A | Ocular targeting compounds and their use in treating ocular diseases | 比奥菲蒂斯公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021130451-A1 | CHEMICAL COMPOUNDS TARGETING THE EYE AND USE THEREOF IN THE TREATMENT OF EYE DISEASES | BIOPHYTIS (FR) | 2021-07-01 | — | — | WO | disclosed |
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| CN-105473585-B | Piperidine carboxylic acid derivative as fungicide | 拜耳作物科学股份公司 | 2018-04-13 | — | — | CN | disclosed |
| WO-2018064356-A1 | COMPOUNDS AND METHODS FOR TREATING LUPUS | CELGENE INTERNATIONAL II SARL (CH) | 2018-04-05 | — | — | WO | disclosed |
| EP-2731932-B1 | AMINOMETHYL QUINOLONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-12-30 | — | — | EP | disclosed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| EP-0889041-B1 | NOVEL IRIDOID DERIVATIVES AND NEOVASCULARIZATION INHIBITORS CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO (JP) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| EP-0889041-A1 | NOVEL IRIDOID DERIVATIVES AND NEOVASCULARIZATION INHIBITORS CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | LMNA 2123/4885L3MBTL1 2102/4885MAPT 4621/4885 |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | LTA4H, LTC4S, LTB4R | LMNA 2793/4885L3MBTL1 1348/4885MAPT 3103/4885 |
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | LMNA 2394/4885L3MBTL1 1782/4885MAPT 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.